Lejla Koric
Overview
Explore the profile of Lejla Koric including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
320
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nicolas G, Zarea A, Lacour M, Quenez O, Rousseau S, Richard A, et al.
Genet Med
. 2024 Jan;
26(5):101082.
PMID: 38281098
Purpose: To assess the likely pathogenic/pathogenic (LP/P) variants rates in Mendelian dementia genes and the moderate-to-strong risk factors rates in patients with Alzheimer disease (AD). Methods: We included 700 patients...
2.
Heim X, Hubert A, Raouak I, Nzepa A, Mege J, Delmont E, et al.
Clin Chem Lab Med
. 2023 Apr;
61(9):1623-1629.
PMID: 37015059
Objectives: Define the cutoff thresholds of the Kappa (K) and Lambda (L) free light chains (FLC) indices for the detection of intrathecal immunoglobulin synthesis (IIS) using the new K and...
3.
Benvenutto A, Guedj E, Felician O, Eusebio A, Azulay J, Ceccaldi M, et al.
J Alzheimers Dis
. 2020 Feb;
74(1):331-343.
PMID: 32039846
Corticobasal syndrome (CBS) is a neuropathologically heterogeneous entity. The use of cerebrospinal fluid and amyloid biomarkers enables detection of underlying Alzheimer's disease (AD) pathology. We thus compared clinical, eye movement,...
4.
Laurens B, Planche V, Cubizolle S, Declerck L, Dupouy S, Formaglio M, et al.
J Alzheimers Dis
. 2019 Aug;
71(2):613-621.
PMID: 31424412
Background/objective: Performances on spatial decision eye-tracking tasks are known to be impaired in patients with moderate Alzheimer's disease (AD), but the clinical relevance of this deficit during earlier stages of...
5.
Bergeron D, Gorno-Tempini M, Rabinovici G, Santos-Santos M, Seeley W, Miller B, et al.
Ann Neurol
. 2018 Sep;
84(5):729-740.
PMID: 30255971
Objective: To estimate the prevalence of amyloid positivity, defined by positron emission tomography (PET)/cerebrospinal fluid (CSF) biomarkers and/or neuropathological examination, in primary progressive aphasia (PPA) variants. Methods: We conducted a...
6.
Holden J, Cosnard A, Laurens B, Asselineau J, Biotti D, Cubizolle S, et al.
J Alzheimers Dis
. 2018 Aug;
65(4):1209-1223.
PMID: 30149445
Saccade alterations are potential early signs of Alzheimer's disease. However, uncertainty persists in how early and reliably automated saccade recording systems detect impairments. This multicenter pathophysiological case-control transversal study explored...
7.
Benvenutto A, Giusiano B, Koric L, Gueriot C, Didic M, Felician O, et al.
J Alzheimers Dis
. 2018 Aug;
65(4):1147-1157.
PMID: 30124446
Background: Neurodegeneration biomarkers are routinely used in the diagnosis of Alzheimer's disease (AD). Objective: To evaluate the respective contributions of two neuroimaging biomarkers, structural MRI and 18FDG-PET, in the assessment...
8.
Aziz A, Giusiano B, Joubert S, Duprat L, Didic M, Gueriot C, et al.
Neurobiol Aging
. 2017 Mar;
54:22-30.
PMID: 28314160
Neuroimaging biomarkers differ between patients with early-onset Alzheimer's disease (EOAD) and late-onset Alzheimer's disease (LOAD). Whether these changes reflect cognitive heterogeneity or differences in disease severity is still unknown. This...
9.
Joubert S, Gour N, Guedj E, Didic M, Gueriot C, Koric L, et al.
Cortex
. 2015 Dec;
74:217-32.
PMID: 26694580
The goal of this study was to investigate the specific patterns of memory breakdown in patients suffering from early-onset Alzheimer's disease (EOAD) and late-onset Alzheimer's disease (LOAD). Twenty EOAD patients,...
10.
Gour N, Felician O, Didic M, Koric L, Gueriot C, Chanoine V, et al.
Hum Brain Mapp
. 2013 Oct;
35(7):2978-94.
PMID: 24123475
At a similar stage, patients with early onset Alzheimer's disease (EOAD) have greater neocortical but less medial temporal lobe dysfunction and atrophy than the late-onset form of the disease (LOAD)....